Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 75 • 2018 ACR/ARHP Annual Meeting
Elevated Oxylipin Profile in Autoantibody-Positive Individuals at-Risk of Developing Rheumatoid Arthritis
Vidyanand Anaparti¹, Irene Smolik², Tanja Winter³, Xiaobo Meng⁴, Harold Aukema³ and Hani El-Gabalawy⁴, ¹Internal Medicine, University of Manitoba, Winnipeg, MB, Canada, ²Arthritis Center, University of Manitoba, Winnipeg, MB, Canada, ³Food and Nutritional Sciences, University of Manitoba, Winnipeg, MB, Canada, ⁴University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Preclinical phase of rheumatoid arthritis (RA) is characterized by presence of autoantibodies, including anti-citrullinated protein antibodies (ACPA), years before disease onset. Epidemiological observations suggest…
Abstract Number: 603 • 2018 ACR/ARHP Annual Meeting
Rheumatologists Beliefs in the Effectiveness of Other Methotrexate-Based Treatment Approaches May Explain the Low Use of Triple Therapy: A Bayesian Belief Elicitation
Gyanendra Pokharel¹, Rob Deardon¹, Sindhu Johnson², George A. Tomlinson³ and Glen Hazlewood⁴, ¹Department of Mathematics and Statistics, University of Calgary, Calgary, AB, Canada, ²Rheumatology, Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, ³Medicine, Mount Sinai Hospital, Toronto, ON, Canada, ⁴Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: Triple therapy (MTX, sulphasalazine (SSZ), hydroxychloroquine (HCQ)) has evidence to support its use from randomized trials (RCTs) but is not commonly used. The objective…
Abstract Number: 1544 • 2018 ACR/ARHP Annual Meeting
Tofacitinib Safety and Efficacy in the Treatment of Rheumatoid Arthritis in a Central/Eastern European Subpopulation
Jiri Vencovsky¹, Janusz Badurski², Šárka Forejtová¹, Olga Lukáčová³, Mykola Stanislavchuk⁴, Daniela Yaneva-Bichovska⁵, Harry Shi⁶, Radu Vasilescu⁷, Tatjana Lukic⁸ and Martin Kabina⁹, ¹Institute of Rheumatology, Prague, Czech Republic, ²Centre of Osteoporosis and Osteoarticular Diseases, Bialystok, Poland, ³National Institute for Rheumatic Diseases, Piešťany, Slovakia, ⁴Vinnytsia Regional Clinical Hospital, Vinnytsia, Ukraine, ⁵Medical Centre Synexus, Sofia, Bulgaria, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Regional Medical Europe, Brussels, Belgium, ⁸Pfizer Inc, New York, NY, ⁹Pfizer Innovative Health, Prague, Czech Republic
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. This post hoc analysis assessed tofacitinib safety and efficacy in the Central…
Abstract Number: 2463 • 2018 ACR/ARHP Annual Meeting
Reducing Time to Treatment in Patients with Early and Uncontrolled RA: Implementation of a Collaborative and Systems-Based Approach to Improve Access to Care
Isabelle Amigues, Department of Medicine, Division of Rheumatology, National Jewish Health, Denver, CO
Reducing Time to Treatment in Patients with Early and Uncontrolled RA: Implementation of a Collaborative and Systems-Based Approach to Improve Access to Care.Background/Purpose: The first…
Abstract Number: 203 • 2018 ACR/ARHP Annual Meeting
Meat Consumption and Risk of Rheumatoid Arthritis in Women: A Population-Based Cohort Study
Daniela Di Giuseppe¹, Lotta Ljung² and Bjorn Sundstrom², ¹Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, ²Department of Public Health and Clinical Medicine/Rheumatology,, Umeå University, Umeå, Sweden
Background/Purpose: Mixed results have been reported for the association between meat consumption and the risk of developing rheumatoid arthritis (RA). The aim of this study…
Abstract Number: 613 • 2018 ACR/ARHP Annual Meeting
Interim Analysis of Baseline Characteristics and Preferences of Administration Route of Rheumatoid Arthritis Patients Who Are Bio-Naïve or Switched between Advanced RA Treatments; A Multicenter, Prospective, Observational Study
Haner Direskeneli¹, Omer Karadag², Aşkın Ateş³, Abdurrahman Tufan⁴, Nevsun Inanc¹, Suleyman Serdar Koca⁵, Gozde Yildirim Cetin⁶, Servet Akar⁷, Muhammet Cinar⁸, Sedat Yılmaz⁸, Neslihan Yilmaz⁹, Ediz Dalkiliç¹⁰, Cemal Bes¹¹, Zeynep Ozbalkan¹², Baris Yilmazer¹³, Ali Şahin¹⁴, Emine Duygu Ersozlu¹⁵, Mehmet Engin Tezcan¹⁶, Nesrin Şen¹⁶, Gokhan Keser¹⁷, Ilkan Tansoker¹⁸, Fatma Basak Hacibedel¹⁹, Kerem Helvacioglu¹⁹ and Levent Mert Gunay¹⁸, ¹Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ²Hacettepe University Faculty of Medicine, Ankara, Turkey, ³Department of Internal Medicine, Division of Rheumatology, Ankara University School of Medicine, Ankara, Turkey, ⁴Internal Medicine-Rheumatology, Gazi University Faculty of Medicine, Ankara, Turkey, ⁵Rheumatology, Firat University Faculty of Medicine, Elazığ, Turkey, ⁶Department of Internal Medicine, Division of Rheumatology, Sutcu Imam University, School of Medicine, Kahramanmaras, Turkey, ⁷Faculty of Medicine, Department of Rheumatology, Izmir Katip Celebi University, Izmir, Turkey, ⁸Rheumatology Division, Gülhane Training and Research Hospital, Ankara, Turkey, ⁹Department of Rheumatology, Bilim University Faculty of Medicine, Istanbul, Turkey, ¹⁰Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey, ¹¹Department of Rheumatology, Health Sciences University Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey, ¹²Rheumatology Division, Ankara Numune Training and Research Hospital, Ankara, Turkey, ¹³Internal Medicine, Rheumatology Division, Çanakkale Onsekiz Mart University Faculty of Medicine, Çanakkale, Turkey, ¹⁴Department of Rheumatology, Cumhuriyet University Faculty of Medicine, Sivas, Turkey, ¹⁵Rheumatology Division, Ministry of Health Adana City Hospital, Adana, Turkey, ¹⁶Rheumatology Division, Ministry of Health İstanbul Kartal Training and Research Hospital, Istanbul, Turkey, ¹⁷Rheumatology, Ege University Medical Faculty, Izmir, Turkey, ¹⁸Medical Department, Pfizer, Istanbul, Turkey, ¹⁹Health Economics and Outcomes Research Department, Pfizer, Istanbul, Turkey
Background/Purpose: To describe the baseline characteristics, patient and physician preferences of rheumatoid arthritis patients treated with biologics or targeted therapies in a real world setting.…
Abstract Number: 1546 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Corticosteroids in Rheumatoid Arthritis: Systematic Literature Review and Practical Recommendations
Raimon Sanmartí¹, Jesús Tornero Molina², Francisco Javier Narváez³, Alejandro Muñoz⁴, Elena Garmendia⁵, Ana M. Ortiz Garcia⁶, Miguel A. Abad⁷, Patricia Moya⁸, Maria Lourdes Mateo⁹, Delia Reina¹⁰, Juan Salvatierra Osorio¹¹, Sergio Rodriguez¹², Ana Rubial Escribano¹³, Natalia Palmou-Fontana¹⁴ and Jaime Calvo-Alén¹⁵, ¹Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, ²Rheumatology Unit, Hospital de Guadalajara, Guadalajara, Spain, ³Rheumatology Department, Hospital Universitario de Bellvitge, Idibell, Barcelona, Spain, ⁴Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain, ⁵Rheumatology, Hospital Universitario Cruces. Barakaldo. Spain, Barakaldo, Spain, ⁶Rheumatology, Rheumatology Service, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, ⁷FEA Reumatología, Hospital Virgen del Puerto, Cáceres, Spain, ⁸Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁹Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, ¹⁰Rheumatology, Hospital Moises Broggi, Sant Joan Despí, Spain, ¹¹Complejo Hospitalario Universitario de Granada, Granada, Spain, ¹²Rheumatology, Hospital Universitario Virgen de Valme, Sevilla, Spain, ¹³Rheumatology, Hospital Alfredo Espinosa, Urduliz, Spain, ¹⁴Hospital Universitario Marqués de Valdecilla, IDIVAL. Universidad of Cantabria, Santander, Spain, ¹⁵Rheumatology Department, Hospital Universitario Araba. Vitoria-Gasteiz, Alava, Spain
Background/Purpose: Corticosteroids are effective in rheumatoid arthritis (RA) patients but their adverse events limit their use. The aim of this study was to: 1) To…
Abstract Number: 2465 • 2018 ACR/ARHP Annual Meeting
Characterizing Palindromic Symptoms in Early Rheumatoid Arthritis: Results from the Canadian Early Arthritis Cohort Study
Leah Ellingwood¹, Orit Schieir², Susan J. Bartlett³, Louis Bessette⁴, Carol A Hitchon⁵, Gilles Boire⁶, Glen Hazlewood⁷, Edward C. Keystone⁸, Diane Tin⁹, Carter Thorne¹⁰, Vivian P. Bykerk¹¹ and Janet E. Pope¹², ¹Department of Internal Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, ²Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ³Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Rheumatology, Laval University, Québec, QC, Canada, ⁵University of Manitoba, Winnipeg, MB, Canada, ⁶Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁷Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, AB, Canada, ⁸University of Toronto and Mount Sinai Hospital, Toronto, ON, Canada, ⁹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰Southlake Regional Health Centre, Newmarket, ON, Canada, ¹¹Hospital for Special Surgery, New York, NY, ¹²Department of Medicine, University of Western Ontario, London, ON, Canada
Background/Purpose: Palindromic rheumatism (PR) (transient acute attacks of articular and/or periarticular inflammation) may progress to rheumatoid arthritis (RA). How often early RA (ERA) patients report…
Abstract Number: 217 • 2018 ACR/ARHP Annual Meeting
Association between Comorbidities and Socioeconomic Status Among Patients with Rheumatoid Arthritis in Korea
Seunghwan Shin¹, Anna Shin¹, Ji Hyoun Kim², You-Jung Ha¹, Yun Jong Lee¹, Yeong Wook Song³ and Eun Ha Kang¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of (South), ²Department of Internal Medicine, Chungbuk National University Hospital, Chungcheongbuk-do, Korea, Republic of (South), ³Seoul National University College of Medicine, Seoul, Korea, Republic of (South)
Background/Purpose: Increased prevalence of comorbidities in patients with rheumatoid arthritis (RA) compared to general population has been noted in several previous study. This study aims…
Abstract Number: 620 • 2018 ACR/ARHP Annual Meeting
Efficacy of a Second Tumor Necrosis Factor Inhibitor (TNFi) in the Treatment of Rheumatoid Arthritis (RA)
Jennifer Reams¹, Andrea Berger², Philip Dunn², Eva O'Connell³, William Torelli², Jason Bankert², Muhammed Bashir² and Alfred Denio¹, ¹Rheumatology, Geisinger Medical Center, Danville, PA, ²Geisinger Medical Center, Danville, PA, ³Internal Medicine, Geisinger Medical Center, Danville, PA
Background/Purpose: The response rate of TNFis in RA is variable and to some extent unpredictable, making treatment decision-making quite complex. Some insurance carriers require RA…
Abstract Number: 1554 • 2018 ACR/ARHP Annual Meeting
Cigarette Smoking Does Not Affect Treatment Response to Tofacitinib in Rheumatoid Arthritis
Ahmet Karatas¹, Burak Oz², Ediz Dalkiliç³, Gerçek Can⁴, Yavuz Pehlivan⁵, Soner Senel⁶, Ayten Yazici⁷, Nevsun Inanc⁸, Zeynep Erturk⁹, Ayse Cefle⁷, Servet Akar¹⁰, Suleyman Serdar Koca¹¹, Merih Birlik⁴ and Fatos Onen⁴, ¹Department of Rheumatology, Firat University, School of Medicine, Rheumatology, Elazig, Turkey, ²Rheumatology, Firat University, School of Medicine, Rheumatology, Elazig, Turkey, ³Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey, ⁴Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, ⁵Rheumatology, Uludag University, Faculty of Medicine, Bursa, Turkey, ⁶Rheumatology, Kayseri Erciyes University, Faculty of Medicine, Kayseri, Turkey, ⁷Rheumatology, Kocaeli University, Faculty of Medicine, Kocaeli, Turkey, ⁸Department of Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, ⁹Department of Internal Medicine, Division of Rheumatology, Marmara University, Istanbul, Turkey, ¹⁰Department of Internal Medicine, Division of Rheumatology,, Izmir Katip Çelebi University Faculty of Medicine, Izmir, Turkey, ¹¹Rheumatology, Firat University Faculty of Medicine, Elazığ, Turkey
Background/Purpose: Smoking is one of the described risk factors for rheumatoid arthritis (RA) since smoking may induce citrullination of peptide antigens and thus the trigger…
Abstract Number: 2476 • 2018 ACR/ARHP Annual Meeting
Analysis of the Disease Activity and Functional Measures of Young Patients with Rheumatoid Arthritis Undergoing Total Joint Arthroplasty By Using the Database of Nation-Wide Observational Cohort
Kimio Masuda¹, Tatsuou Ikenaka¹, Toshihiro Matsui² and Shigeto Tohma³, ¹Department of Rehabilitation Medicine, National Hospital Organization Sagamihara Hospital, Sagamihara, Japan, ²Department of Rheumatology, National Hospital Organization Sagamihara Hospital, Sagamihara, Japan, ³National Hospital Organization Tokyo National Hospital, Kiyose, Japan
Background/Purpose: The aim of this study was to investigate the impact of total joint arthroplasty (TJA) on the disease activity and functional measures of young…
Abstract Number: 221 • 2018 ACR/ARHP Annual Meeting
Distal Interphalangeal Joint Involvement and Its Association with Disease Activity in Rheumatoid Arthritis (RA): Analysis Based on a Nationwide RA Database in Japan
Tetsuji Sawada¹, Susumu Nishiyama², Mayu Tago³, Koichiro Tahara³, Eri Kato¹, Hiroaki Mori³, Haeru Hayashi³, Toshihiro Matsui⁴, Jinju Nishino⁵ and Shigeto Tohma⁶, ¹Rheumatology, Tokyo Medical University, Shinjuku Tokyo, Japan, ²Rheumatic Disease Center, Kurashiki Medical Center, Okayama, Japan, ³Rheumatology, Tokyo Medical University, Tokyo, Japan, ⁴National Hospital Organization Sagamihara l Hospital, Clinical Research Center for Allergy and Rheumatology, Kanagawa, Japan, ⁵Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan, ⁶National Hospital Organization Tokyo National Hospital, Kiyose, Japan
Background/Purpose: Distal interphalangeal (DIP) joint arthropathy is characteristic of both psoriatic arthritis and osteoarthritis, but it has long been pointed out that DIP joints can…
Abstract Number: 626 • 2018 ACR/ARHP Annual Meeting
The Comparative Effectiveness of Cycling Tumor Necrosis Factor Inhibitor (TNFi) Versus Swapping to a Nontnfi on Patient-Reported Functional Ability of Patients with Rheumatoid Arthritis
Maria A. Lopez-Olivo¹, Aliza Matusevich², Scott B. Cantor³, Gregory Pratt⁴ and Maria Suarez-Almazor⁵, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, ²Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ³Department of Health Services Research, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ⁴Research Medical Library, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ⁵Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, Houston, TX
Background/Purpose: Data on patient-reported functional ability to evaluate the optimal strategy for patients who have failed to first TNFi is scarce. Patient-reported outcomes are a…
Abstract Number: 1863 • 2018 ACR/ARHP Annual Meeting
Anti-Cyclic Citrullinated Protein Antibody at Multiple Cutoff Levels and in Combination with Rheumatoid Factor IgM and Serum Calprotectin Is Highly Specific for the Development of Rheumatoid Arthritis within 3 Years
Leah F. Bettner¹, Lindsay B. Kelmenson¹, M. Kristen Demoruelle¹, Ted R. Mikuls², Jess Edison³, Elizabeth A. Mewshaw⁴, Mark C. Parish¹, Marie L. Feser¹, Ashley A. Frazer-Abel¹, LauraKay Moss¹, Michael Mahler⁵, V. Michael Holers⁶ and Kevin D. Deane¹, ¹Division of Rheumatology, University of Colorado Denver, Aurora, CO, ²Internal Medicine, Division of Rheumatology, VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ³Division of Rheumatology, Walter Reed National Military Medical Center, Bethesda, MD, ⁴Walter Reed National Military Medical Center, Bethesda, MD, ⁵Research and Development, Inova Diagnostics, San Diego, CA, ⁶Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Serum elevations of antibodies to citrullinated protein antigens (ACPA) and rheumatoid factor (RF) can identify individuals at risk for developing rheumatoid arthritis (RA). Prior…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].